Kura Oncology, Inc. (KURA)
10.65
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
10.72
+0.07
(+0.66%)
After-Hours: 20:00
Kura Oncology Net Income (Quarterly) : -68.33M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -68.33M |
| March 31, 2026 | -73.33M |
| December 31, 2025 | -81.00M |
| September 30, 2025 | -74.12M |
| June 30, 2025 | -66.12M |
| March 31, 2025 | -57.43M |
| December 31, 2024 | -19.22M |
| September 30, 2024 | -54.40M |
| June 30, 2024 | -50.84M |
| March 31, 2024 | -49.52M |
| December 31, 2023 | -42.79M |
| September 30, 2023 | -38.60M |
| June 30, 2023 | -37.17M |
| March 31, 2023 | -34.07M |
| December 31, 2022 | -33.11M |
| September 30, 2022 | -35.50M |
| June 30, 2022 | -34.77M |
| March 31, 2022 | -32.45M |
| December 31, 2021 | -32.74M |
| September 30, 2021 | -33.37M |
| June 30, 2021 | -33.66M |
| March 31, 2021 | -30.69M |
| December 31, 2020 | -26.16M |
| Date | Value |
|---|---|
| September 30, 2020 | -23.77M |
| June 30, 2020 | -20.49M |
| March 31, 2020 | -19.21M |
| December 31, 2019 | -17.86M |
| September 30, 2019 | -16.39M |
| June 30, 2019 | -14.94M |
| March 31, 2019 | -13.94M |
| December 31, 2018 | -16.10M |
| September 30, 2018 | -15.01M |
| June 30, 2018 | -14.74M |
| March 31, 2018 | -14.60M |
| December 31, 2017 | -10.75M |
| September 30, 2017 | -9.333M |
| June 30, 2017 | -7.82M |
| March 31, 2017 | -7.533M |
| December 31, 2016 | -7.347M |
| September 30, 2016 | -6.926M |
| June 30, 2016 | -6.661M |
| March 31, 2016 | -6.626M |
| December 31, 2015 | -6.474M |
| September 30, 2015 | -6.09M |
| June 30, 2015 | -5.585M |
| March 31, 2015 | -4.476M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -6.012M |
| Fortress Biotech, Inc. | 0.602M |
| Spero Therapeutics, Inc. | -9.552M |
| Gossamer Bio, Inc. | 16.90M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 20.87M |
| Total Expenses (Quarterly) | 89.20M |
| EPS Diluted (Quarterly) | -0.769 |
| Enterprise Value | 452.79M |
| Gross Profit Margin (Quarterly) | 97.07% |
| Profit Margin (Quarterly) | -327.3% |
| Earnings Yield | -31.57% |
| Normalized Earnings Yield | -31.57 |